- Report
- July 2026
- 254 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Clinical Trials
- May 2026
- 80 Pages
Global
From €1810EUR$2,000USD£1,546GBP
- Report
- May 2026
- 100 Pages
Global
From €2442EUR$2,699USD£2,086GBP
- Report
- May 2026
- 100 Pages
Global
From €2442EUR$2,699USD£2,086GBP
- Report
- June 2026
- 144 Pages
Global
From €3619EUR$3,999USD£3,091GBP
- Report
- June 2026
- 137 Pages
Global
From €3619EUR$3,999USD£3,091GBP
- Report
- January 2026
- 149 Pages
Global
From €3574EUR$3,950USD£3,053GBP
- Report
- September 2025
- 113 Pages
Global
From €3500EUR$4,143USD£3,094GBP
- Report
- December 2025
- 163 Pages
Global
From €4389EUR$4,850USD£3,749GBP
- Report
- March 2024
- 102 Pages
Global
From €1538EUR$1,700USD£1,314GBP
- Report
- June 2025
- 110 Pages
Global
From €5384EUR$5,950USD£4,599GBP
- Report
- May 2024
- 137 Pages
Global
From €3619EUR$3,999USD£3,091GBP
- Report
- June 2025
- 110 Pages
Global
From €4434EUR$4,900USD£3,787GBP
- Report
- October 2023
- 145 Pages
Global
From €2850EUR$3,150USD£2,435GBP
- Report
- August 2022
Global
From €4072EUR$4,500USD£3,478GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1131EUR$1,250USD£966GBP
- Drug Pipelines
- April 2025
- 250 Pages
Global
From €2715EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1131EUR$1,250USD£966GBP
- Report
- May 2024
- 137 Pages
Global
From €3619EUR$3,999USD£3,091GBP

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery.
Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia.
Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more